Sporadic versus Radiation-Associated Angiosarcoma: A Comparative Clinicopathologic and Molecular Analysis of 48 Cases

• Main Authors: Jennifer Hung, Susan M. Hiniker, David R. Lucas, Kent A. Griffith, Jonathan B. McHugh, Amichay Meirovitz, Dafydd G. Thomas, Rashmi Chugh, Joseph M. Herman
• Format: Article
• Language: English
• Published: Hindawi Limited 2013-01-01
• Series: Sarcoma
• Online Access: http://dx.doi.org/10.1155/2013/798403

Angiosarcomas are aggressive tumors of vascular endothelial origin, occurring sporadically or in association with prior radiotherapy. We compared clinicopathologic and biologic features of sporadic angiosarcomas (SA) and radiation-associated angiosarcomas (RAA). Methods. From a University of Michigan institutional database, 37 SA and 11 RAA were identified. Tissue microarrays were stained for p53, Ki-67, and hTERT. DNA was evaluated for TP53 and ATM mutations. Results. Mean latency between radiotherapy and diagnosis of RAA was 11.9 years: 6.7 years for breast RAA versus 20.9 years for nonbreast RAA (P=0.148). Survival after diagnosis did not significantly differ between SA and RAA (P=0.590). Patients with nonbreast RAA had shorter overall survival than patients with breast RAA (P=0.03). The majority of SA (86.5%) and RAA (77.8%) were classified as high-grade sarcomas (P=0.609). RAA were more likely to have well-defined vasoformative areas (55.6% versus 27%, P=0.127). Most breast SA were parenchymal in origin (80%), while most breast RAA were cutaneous in origin (80%). TMA analysis showed p53 overexpression in 25.7% of SA and 0% RAA, high Ki-67 in 35.3% of SA and 44.4% RAA, and hTERT expression in 100% of SA and RAA. TP53 mutations were detected in 13.5% of SA and 11.1% RAA. ATM mutations were not detected in either SA or RAA. Conclusions. SA and RAA are similar in histology, immunohistochemical markers, and DNA mutation profiles and share similar prognosis. Breast RAA have a shorter latency period compared to nonbreast RAA and a significantly longer survival.